The success rate of clinical trials for treatments for major diseases is currently the lowest for cancer. Cancer will soon overtake heart disease as the top cause of death in affluent nations, in part due to the dearth of effective anti-cancer medications. Cancer presents complex problems that might be helped by bringing together experts from a wide range of related and unrelated professions because it is a disease that is deeply ingrained in the biology of our body. The discovery of therapies to halt disease progression and extend patient lives could be made possible by combining existing approaches with novel ones in order to address this difficult health issue. A recent workshop with the theme "Rethinking Cancer" was inspired by this objective. The 35 participants in this workshop, the bulk of whom were academics with a small number of scientists from business, mainly discussed why model systems can be cured of cancer while individuals are frequently unable to. One overriding finding is that the primary goal of cancer biology must shift from the identification of fundamental biological processes required to comprehend cancer to the clinical application of these findings. The lesson is to keep an eye on therapies throughout the discovery phase rather than giving up on the desire to comprehend the basic biology of cancer. Research has traditionally focused on understanding the factors that contribute to tumour progression; however, therapeutically focusing on these factors can result in unacceptable damage due to their functions in overall body function.

Understanding pharmaceutical terms like on- and off-target physiological effects, tumour shrinkage, pharmacokinetics and pharmacodynamics (PK/PD), therapeutic window (defined by the balance of efficacy and toxicity), and maximum tolerated dose is crucial when advancing promising drug hits toward the clinic (MTD; the highest drug dose that does not cause unacceptable side effects). The identification of platforms that can quickly detect hazardous effects should be the main goal of research. Focusing on leads that are expected to exhibit "druggable" characteristics should be made possible by involving chemists early in the discovery process.

Although there has been a noticeable advancement in this area in recent years, a suitable environment for clinical research still has to be created. This entails teaching community doctors, medical college instructors, and graduate and postgraduate medical students about translational clinical research and creating a suitable infrastructure. The Indian pharmaceutical sector has experienced spectacular growth in the area of generic molecules; they need to make investments in the creation of new molecules and cancer research that is specifically focused on India.

Cancer Clinical Research peer reviewed, open access periodical dedicated to publish the clinical advancements in the cancer research and therapy providing end-to-end solutions, from diagnosis thorough various stages of cancer therapy, pharmaceutical advancements, drug delivery, clinical trials, rehabilitation and care.

Authors can submit their manuscripts as an email attachment to ccr@alliedacademiesscholars.com.

Best Wishes,

Journal Co-ordinator

Journal of Cancer Clinical Research